nodes	percent_of_prediction	percent_of_DWPC	metapath
Vismodegib—Etoricoxib—Vemurafenib—skin cancer	0.323	1	CrCrCtD
Vismodegib—SHH—skin cancer	0.251	0.635	CbGaD
Vismodegib—SMO—skin cancer	0.144	0.365	CbGaD
Vismodegib—ORM1—Vemurafenib—skin cancer	0.043	0.236	CbGbCtD
Vismodegib—ABCG2—Vemurafenib—skin cancer	0.0263	0.144	CbGbCtD
Vismodegib—ALB—Vemurafenib—skin cancer	0.0181	0.0993	CbGbCtD
Vismodegib—ABCG2—Dactinomycin—skin cancer	0.0174	0.0957	CbGbCtD
Vismodegib—ABCG2—Fluorouracil—skin cancer	0.0118	0.0647	CbGbCtD
Vismodegib—CYP3A4—Imiquimod—skin cancer	0.0104	0.0568	CbGbCtD
Vismodegib—CYP3A4—Temozolomide—skin cancer	0.0104	0.0568	CbGbCtD
Vismodegib—ABCG2—Docetaxel—skin cancer	0.00901	0.0494	CbGbCtD
Vismodegib—ALB—Fluorouracil—skin cancer	0.00813	0.0446	CbGbCtD
Vismodegib—ABCB1—Dactinomycin—skin cancer	0.00629	0.0345	CbGbCtD
Vismodegib—CYP2C8—Fluorouracil—skin cancer	0.00628	0.0345	CbGbCtD
Vismodegib—CYP3A4—Vemurafenib—skin cancer	0.00567	0.0311	CbGbCtD
Vismodegib—SHH—forelimb—skin cancer	0.0047	0.199	CbGeAlD
Vismodegib—CYP2C9—Fluorouracil—skin cancer	0.00438	0.024	CbGbCtD
Vismodegib—SHH—appendage—skin cancer	0.00363	0.153	CbGeAlD
Vismodegib—ABCB1—Docetaxel—skin cancer	0.00325	0.0178	CbGbCtD
Vismodegib—SHH—skin epidermis—skin cancer	0.00302	0.128	CbGeAlD
Vismodegib—SHH—Hedgehog Signaling Pathway—PTCH2—skin cancer	0.00238	0.0448	CbGpPWpGaD
Vismodegib—SMO—Hedgehog Signaling Pathway—PTCH2—skin cancer	0.00226	0.0425	CbGpPWpGaD
Vismodegib—SHH—hair follicle—skin cancer	0.00215	0.091	CbGeAlD
Vismodegib—SHH—Glypican 3 network—PTCH1—skin cancer	0.00202	0.0381	CbGpPWpGaD
Vismodegib—CYP3A4—Docetaxel—skin cancer	0.00195	0.0107	CbGbCtD
Vismodegib—SHH—Hedgehog Signaling Pathway—GLI2—skin cancer	0.0018	0.034	CbGpPWpGaD
Vismodegib—SHH—Signaling events mediated by the Hedgehog family—PTCH2—skin cancer	0.00178	0.0335	CbGpPWpGaD
Vismodegib—SMO—Hedgehog Signaling Pathway—GLI2—skin cancer	0.00171	0.0322	CbGpPWpGaD
Vismodegib—SHH—Hedgehog Signaling Pathway—GLI1—skin cancer	0.0017	0.032	CbGpPWpGaD
Vismodegib—SMO—Signaling events mediated by the Hedgehog family—PTCH2—skin cancer	0.00169	0.0318	CbGpPWpGaD
Vismodegib—SHH—Hedgehog Signaling Pathway—SUFU—skin cancer	0.00161	0.0303	CbGpPWpGaD
Vismodegib—SMO—Hedgehog Signaling Pathway—GLI1—skin cancer	0.00161	0.0303	CbGpPWpGaD
Vismodegib—SMO—Hedgehog Signaling Pathway—SUFU—skin cancer	0.00152	0.0287	CbGpPWpGaD
Vismodegib—SHH—Signaling events mediated by the Hedgehog family—GLI2—skin cancer	0.00135	0.0254	CbGpPWpGaD
Vismodegib—SMO—Signaling events mediated by the Hedgehog family—GLI2—skin cancer	0.00128	0.0241	CbGpPWpGaD
Vismodegib—SHH—Hedgehog Signaling Pathway—PTCH1—skin cancer	0.00116	0.0219	CbGpPWpGaD
Vismodegib—SHH—Hedgehog Signaling Pathway—SMO—skin cancer	0.00116	0.0219	CbGpPWpGaD
Vismodegib—SMO—Hedgehog Signaling Pathway—SHH—skin cancer	0.00116	0.0219	CbGpPWpGaD
Vismodegib—SMO—Hedgehog Signaling Pathway—PTCH1—skin cancer	0.0011	0.0208	CbGpPWpGaD
Vismodegib—SHH—Dopaminergic Neurogenesis—GLI2—skin cancer	0.00109	0.0206	CbGpPWpGaD
Vismodegib—SHH—connective tissue—skin cancer	0.00104	0.0438	CbGeAlD
Vismodegib—SHH—Dopaminergic Neurogenesis—GLI1—skin cancer	0.00103	0.0193	CbGpPWpGaD
Vismodegib—SMO—nipple—skin cancer	0.00102	0.0432	CbGeAlD
Vismodegib—SHH—epithelium—skin cancer	0.000983	0.0416	CbGeAlD
Vismodegib—SHH—skin of body—skin cancer	0.000935	0.0395	CbGeAlD
Vismodegib—SHH—Signaling events mediated by the Hedgehog family—SMO—skin cancer	0.00087	0.0164	CbGpPWpGaD
Vismodegib—SMO—Signaling events mediated by the Hedgehog family—SHH—skin cancer	0.00087	0.0164	CbGpPWpGaD
Vismodegib—SHH—Signaling events mediated by the Hedgehog family—PTCH1—skin cancer	0.00087	0.0164	CbGpPWpGaD
Vismodegib—SMO—Signaling events mediated by the Hedgehog family—PTCH1—skin cancer	0.000825	0.0155	CbGpPWpGaD
Vismodegib—SHH—Hedgehog signaling events mediated by Gli proteins—GLI2—skin cancer	0.000749	0.0141	CbGpPWpGaD
Vismodegib—Sorafenib—BRAF—skin cancer	0.000743	0.617	CrCbGaD
Vismodegib—SHH—female reproductive system—skin cancer	0.000731	0.0309	CbGeAlD
Vismodegib—SMO—connective tissue—skin cancer	0.000724	0.0306	CbGeAlD
Vismodegib—SMO—Hedgehog signaling events mediated by Gli proteins—GLI2—skin cancer	0.00071	0.0134	CbGpPWpGaD
Vismodegib—SHH—Hedgehog signaling events mediated by Gli proteins—GLI1—skin cancer	0.000705	0.0133	CbGpPWpGaD
Vismodegib—SHH—Hedgehog signaling events mediated by Gli proteins—SUFU—skin cancer	0.000668	0.0126	CbGpPWpGaD
Vismodegib—SMO—Hedgehog signaling events mediated by Gli proteins—GLI1—skin cancer	0.000668	0.0126	CbGpPWpGaD
Vismodegib—SMO—skin of body—skin cancer	0.000654	0.0276	CbGeAlD
Vismodegib—Neoplasm malignant—Vemurafenib—skin cancer	0.000641	0.0288	CcSEcCtD
Vismodegib—SMO—Hedgehog signaling events mediated by Gli proteins—SUFU—skin cancer	0.000633	0.0119	CbGpPWpGaD
Vismodegib—SHH—Class B/2 (Secretin family receptors)—PTCH2—skin cancer	0.000614	0.0116	CbGpPWpGaD
Vismodegib—SHH—head—skin cancer	0.00061	0.0258	CbGeAlD
Vismodegib—SMO—mammalian vulva—skin cancer	0.000597	0.0252	CbGeAlD
Vismodegib—SMO—Class B/2 (Secretin family receptors)—PTCH2—skin cancer	0.000582	0.011	CbGpPWpGaD
Vismodegib—Musculoskeletal pain—Vemurafenib—skin cancer	0.000554	0.0249	CcSEcCtD
Vismodegib—SHH—Hair Follicle Development: Induction (Part 1 of 3)—SMO—skin cancer	0.000537	0.0101	CbGpPWpGaD
Vismodegib—SHH—Hair Follicle Development: Induction (Part 1 of 3)—PTCH1—skin cancer	0.000537	0.0101	CbGpPWpGaD
Vismodegib—SMO—Hair Follicle Development: Induction (Part 1 of 3)—SHH—skin cancer	0.000537	0.0101	CbGpPWpGaD
Vismodegib—SMO—female reproductive system—skin cancer	0.000511	0.0216	CbGeAlD
Vismodegib—SMO—Hair Follicle Development: Induction (Part 1 of 3)—PTCH1—skin cancer	0.000509	0.00959	CbGpPWpGaD
Vismodegib—Hepatic enzyme increased—Imiquimod—skin cancer	0.000493	0.0222	CcSEcCtD
Vismodegib—SHH—Hedgehog signaling events mediated by Gli proteins—PTCH1—skin cancer	0.000483	0.00909	CbGpPWpGaD
Vismodegib—SMO—Hedgehog signaling events mediated by Gli proteins—SHH—skin cancer	0.000483	0.00909	CbGpPWpGaD
Vismodegib—SHH—Hedgehog signaling events mediated by Gli proteins—SMO—skin cancer	0.000483	0.00909	CbGpPWpGaD
Vismodegib—SMO—Hedgehog signaling events mediated by Gli proteins—PTCH1—skin cancer	0.000458	0.00862	CbGpPWpGaD
Vismodegib—SMO—head—skin cancer	0.000427	0.018	CbGeAlD
Vismodegib—SMO—Hedgehog 'off' state—GLI2—skin cancer	0.000401	0.00756	CbGpPWpGaD
Vismodegib—Pain in extremity—Vemurafenib—skin cancer	0.000397	0.0179	CcSEcCtD
Vismodegib—SHH—Signaling by Hedgehog—GLI2—skin cancer	0.000378	0.00711	CbGpPWpGaD
Vismodegib—SMO—Hedgehog 'off' state—GLI1—skin cancer	0.000377	0.00711	CbGpPWpGaD
Vismodegib—SMO—Signaling by Hedgehog—GLI2—skin cancer	0.000358	0.00674	CbGpPWpGaD
Vismodegib—SMO—Hedgehog 'off' state—SUFU—skin cancer	0.000358	0.00674	CbGpPWpGaD
Vismodegib—SHH—Signaling by Hedgehog—GLI1—skin cancer	0.000355	0.00669	CbGpPWpGaD
Vismodegib—Pain in extremity—Imiquimod—skin cancer	0.000339	0.0152	CcSEcCtD
Vismodegib—SHH—Signaling by Hedgehog—SUFU—skin cancer	0.000337	0.00634	CbGpPWpGaD
Vismodegib—SMO—Signaling by Hedgehog—GLI1—skin cancer	0.000337	0.00634	CbGpPWpGaD
Vismodegib—SMO—Signaling by Hedgehog—SUFU—skin cancer	0.000319	0.00601	CbGpPWpGaD
Vismodegib—Amenorrhoea—Temozolomide—skin cancer	0.000318	0.0143	CcSEcCtD
Vismodegib—Weight decreased—Vemurafenib—skin cancer	0.00031	0.014	CcSEcCtD
Vismodegib—Breast disorder—Imiquimod—skin cancer	0.000306	0.0138	CcSEcCtD
Vismodegib—SHH—Class B/2 (Secretin family receptors)—SMO—skin cancer	0.0003	0.00565	CbGpPWpGaD
Vismodegib—SHH—Class B/2 (Secretin family receptors)—PTCH1—skin cancer	0.0003	0.00565	CbGpPWpGaD
Vismodegib—SMO—Class B/2 (Secretin family receptors)—SHH—skin cancer	0.0003	0.00565	CbGpPWpGaD
Vismodegib—SMO—lymph node—skin cancer	0.000299	0.0126	CbGeAlD
Vismodegib—Hepatic enzyme increased—Temozolomide—skin cancer	0.000296	0.0133	CcSEcCtD
Vismodegib—Etoricoxib—PTGS2—skin cancer	0.000291	0.241	CrCbGaD
Vismodegib—SMO—Class B/2 (Secretin family receptors)—PTCH1—skin cancer	0.000284	0.00536	CbGpPWpGaD
Vismodegib—Musculoskeletal pain—Temozolomide—skin cancer	0.000283	0.0127	CcSEcCtD
Vismodegib—Phosphatase alkaline increased—Temozolomide—skin cancer	0.00028	0.0126	CcSEcCtD
Vismodegib—ABCG2—Fluoropyrimidine Activity—XRCC3—skin cancer	0.00027	0.00509	CbGpPWpGaD
Vismodegib—Connective tissue disorder—Vemurafenib—skin cancer	0.00027	0.0122	CcSEcCtD
Vismodegib—SMO—Hedgehog 'off' state—PTCH1—skin cancer	0.000259	0.00487	CbGpPWpGaD
Vismodegib—SHH—Signaling by Hedgehog—PTCH1—skin cancer	0.000243	0.00458	CbGpPWpGaD
Vismodegib—SHH—Signaling by Hedgehog—SMO—skin cancer	0.000243	0.00458	CbGpPWpGaD
Vismodegib—SMO—Signaling by Hedgehog—SHH—skin cancer	0.000243	0.00458	CbGpPWpGaD
Vismodegib—Alopecia—Vemurafenib—skin cancer	0.000243	0.0109	CcSEcCtD
Vismodegib—Malnutrition—Vemurafenib—skin cancer	0.000239	0.0108	CcSEcCtD
Vismodegib—Dysgeusia—Vemurafenib—skin cancer	0.000234	0.0105	CcSEcCtD
Vismodegib—Blood alkaline phosphatase increased—Temozolomide—skin cancer	0.000233	0.0105	CcSEcCtD
Vismodegib—Back pain—Vemurafenib—skin cancer	0.000231	0.0104	CcSEcCtD
Vismodegib—SMO—Signaling by Hedgehog—PTCH1—skin cancer	0.000231	0.00435	CbGpPWpGaD
Vismodegib—Connective tissue disorder—Imiquimod—skin cancer	0.00023	0.0104	CcSEcCtD
Vismodegib—Ageusia—Docetaxel—skin cancer	0.000229	0.0103	CcSEcCtD
Vismodegib—ORM1—female reproductive system—skin cancer	0.000223	0.00944	CbGeAlD
Vismodegib—Amenorrhoea—Docetaxel—skin cancer	0.000212	0.00953	CcSEcCtD
Vismodegib—Alopecia—Imiquimod—skin cancer	0.000207	0.00932	CcSEcCtD
Vismodegib—Malnutrition—Imiquimod—skin cancer	0.000204	0.00918	CcSEcCtD
Vismodegib—Arthralgia—Vemurafenib—skin cancer	0.000204	0.00917	CcSEcCtD
Vismodegib—Myalgia—Vemurafenib—skin cancer	0.000204	0.00917	CcSEcCtD
Vismodegib—Unspecified disorder of skin and subcutaneous tissue—Vemurafenib—skin cancer	0.000202	0.0091	CcSEcCtD
Vismodegib—Aspartate aminotransferase increased—Dactinomycin—skin cancer	0.000202	0.0091	CcSEcCtD
Vismodegib—Back pain—Imiquimod—skin cancer	0.000197	0.00888	CcSEcCtD
Vismodegib—Nervous system disorder—Vemurafenib—skin cancer	0.000191	0.00862	CcSEcCtD
Vismodegib—Skin disorder—Vemurafenib—skin cancer	0.00019	0.00853	CcSEcCtD
Vismodegib—Dehydration—Temozolomide—skin cancer	0.000189	0.0085	CcSEcCtD
Vismodegib—Weight decreased—Bleomycin—skin cancer	0.000188	0.00847	CcSEcCtD
Vismodegib—Phosphatase alkaline increased—Docetaxel—skin cancer	0.000186	0.00837	CcSEcCtD
Vismodegib—Hypokalaemia—Temozolomide—skin cancer	0.000185	0.00831	CcSEcCtD
Vismodegib—Breast disorder—Temozolomide—skin cancer	0.000183	0.00826	CcSEcCtD
Vismodegib—Aspartate aminotransferase increased—Temozolomide—skin cancer	0.000183	0.00823	CcSEcCtD
Vismodegib—ABCB1—blood vessel—skin cancer	0.000182	0.00771	CbGeAlD
Vismodegib—Musculoskeletal discomfort—Vemurafenib—skin cancer	0.000178	0.008	CcSEcCtD
Vismodegib—Myalgia—Imiquimod—skin cancer	0.000174	0.00782	CcSEcCtD
Vismodegib—Arthralgia—Imiquimod—skin cancer	0.000174	0.00782	CcSEcCtD
Vismodegib—SHH—Validated transcriptional targets of TAp63 isoforms—CDKN2A—skin cancer	0.000173	0.00325	CbGpPWpGaD
Vismodegib—Unspecified disorder of skin and subcutaneous tissue—Imiquimod—skin cancer	0.000172	0.00776	CcSEcCtD
Vismodegib—ABCG2—HIF-1-alpha transcription factor network—PLIN2—skin cancer	0.000171	0.00323	CbGpPWpGaD
Vismodegib—Sulfasalazine—PTGS2—skin cancer	0.000171	0.142	CrCbGaD
Vismodegib—Decreased appetite—Vemurafenib—skin cancer	0.00017	0.00764	CcSEcCtD
Vismodegib—Gastrointestinal disorder—Vemurafenib—skin cancer	0.000168	0.00759	CcSEcCtD
Vismodegib—Fatigue—Vemurafenib—skin cancer	0.000168	0.00757	CcSEcCtD
Vismodegib—SHH—GPCR ligand binding—PTCH2—skin cancer	0.000168	0.00316	CbGpPWpGaD
Vismodegib—Constipation—Vemurafenib—skin cancer	0.000167	0.00751	CcSEcCtD
Vismodegib—Nervous system disorder—Imiquimod—skin cancer	0.000163	0.00735	CcSEcCtD
Vismodegib—Skin disorder—Imiquimod—skin cancer	0.000162	0.00728	CcSEcCtD
Vismodegib—SHH—Integrated Pancreatic Cancer Pathway—SMO—skin cancer	0.00016	0.00301	CbGpPWpGaD
Vismodegib—SMO—Integrated Pancreatic Cancer Pathway—SHH—skin cancer	0.00016	0.00301	CbGpPWpGaD
Vismodegib—SMO—GPCR ligand binding—PTCH2—skin cancer	0.000159	0.003	CbGpPWpGaD
Vismodegib—Weight decreased—Temozolomide—skin cancer	0.000159	0.00714	CcSEcCtD
Vismodegib—ABCG2—mammalian vulva—skin cancer	0.000156	0.0066	CbGeAlD
Vismodegib—Blood alkaline phosphatase increased—Docetaxel—skin cancer	0.000155	0.00698	CcSEcCtD
Vismodegib—Musculoskeletal discomfort—Imiquimod—skin cancer	0.000152	0.00683	CcSEcCtD
Vismodegib—Alopecia—Bleomycin—skin cancer	0.000147	0.00662	CcSEcCtD
Vismodegib—Dyspepsia—Imiquimod—skin cancer	0.000146	0.0066	CcSEcCtD
Vismodegib—Decreased appetite—Imiquimod—skin cancer	0.000145	0.00651	CcSEcCtD
Vismodegib—Gastrointestinal disorder—Imiquimod—skin cancer	0.000144	0.00647	CcSEcCtD
Vismodegib—Fatigue—Imiquimod—skin cancer	0.000143	0.00646	CcSEcCtD
Vismodegib—Pain—Imiquimod—skin cancer	0.000142	0.00641	CcSEcCtD
Vismodegib—Asthenia—Vemurafenib—skin cancer	0.00014	0.0063	CcSEcCtD
Vismodegib—ALB—FOXA2 and FOXA3 transcription factor networks—NKX2-1—skin cancer	0.000139	0.00261	CbGpPWpGaD
Vismodegib—Pruritus—Vemurafenib—skin cancer	0.000138	0.00622	CcSEcCtD
Vismodegib—Connective tissue disorder—Temozolomide—skin cancer	0.000138	0.00621	CcSEcCtD
Vismodegib—CYP2C8—female reproductive system—skin cancer	0.000138	0.00581	CbGeAlD
Vismodegib—Alopecia—Dactinomycin—skin cancer	0.000137	0.00617	CcSEcCtD
Vismodegib—Gastrointestinal pain—Imiquimod—skin cancer	0.000136	0.00613	CcSEcCtD
Vismodegib—Hyponatraemia—Docetaxel—skin cancer	0.000135	0.0061	CcSEcCtD
Vismodegib—Pain in extremity—Docetaxel—skin cancer	0.000135	0.00608	CcSEcCtD
Vismodegib—Diarrhoea—Vemurafenib—skin cancer	0.000134	0.00601	CcSEcCtD
Vismodegib—Abdominal pain—Imiquimod—skin cancer	0.000132	0.00592	CcSEcCtD
Vismodegib—ORM1—lymph node—skin cancer	0.000131	0.00552	CbGeAlD
Vismodegib—Dehydration—Docetaxel—skin cancer	0.000125	0.00565	CcSEcCtD
Vismodegib—Vomiting—Vemurafenib—skin cancer	0.000124	0.00559	CcSEcCtD
Vismodegib—Alopecia—Temozolomide—skin cancer	0.000124	0.00558	CcSEcCtD
Vismodegib—Myalgia—Bleomycin—skin cancer	0.000123	0.00555	CcSEcCtD
Vismodegib—Abdominal pain upper—Docetaxel—skin cancer	0.000123	0.00555	CcSEcCtD
Vismodegib—Rash—Vemurafenib—skin cancer	0.000123	0.00554	CcSEcCtD
Vismodegib—Dermatitis—Vemurafenib—skin cancer	0.000123	0.00553	CcSEcCtD
Vismodegib—CYP2C9—female reproductive system—skin cancer	0.000122	0.00516	CbGeAlD
Vismodegib—Malnutrition—Temozolomide—skin cancer	0.000122	0.0055	CcSEcCtD
Vismodegib—Breast disorder—Docetaxel—skin cancer	0.000122	0.00549	CcSEcCtD
Vismodegib—Aspartate aminotransferase increased—Docetaxel—skin cancer	0.000122	0.00547	CcSEcCtD
Vismodegib—SHH—GPCR ligand binding—MC1R—skin cancer	0.000121	0.00229	CbGpPWpGaD
Vismodegib—Dysgeusia—Temozolomide—skin cancer	0.00012	0.00539	CcSEcCtD
Vismodegib—Asthenia—Imiquimod—skin cancer	0.000119	0.00538	CcSEcCtD
Vismodegib—Back pain—Temozolomide—skin cancer	0.000118	0.00532	CcSEcCtD
Vismodegib—Pruritus—Imiquimod—skin cancer	0.000118	0.0053	CcSEcCtD
Vismodegib—Nausea—Vemurafenib—skin cancer	0.000116	0.00522	CcSEcCtD
Vismodegib—SMO—GPCR ligand binding—MC1R—skin cancer	0.000115	0.00217	CbGpPWpGaD
Vismodegib—Myalgia—Dactinomycin—skin cancer	0.000115	0.00518	CcSEcCtD
Vismodegib—ALB—lymph node—skin cancer	0.000115	0.00484	CbGeAlD
Vismodegib—Alopecia—Fluorouracil—skin cancer	0.000114	0.00515	CcSEcCtD
Vismodegib—Diarrhoea—Imiquimod—skin cancer	0.000114	0.00513	CcSEcCtD
Vismodegib—Musculoskeletal discomfort—Bleomycin—skin cancer	0.000108	0.00485	CcSEcCtD
Vismodegib—Vomiting—Imiquimod—skin cancer	0.000106	0.00476	CcSEcCtD
Vismodegib—Weight decreased—Docetaxel—skin cancer	0.000106	0.00475	CcSEcCtD
Vismodegib—Rash—Imiquimod—skin cancer	0.000105	0.00472	CcSEcCtD
Vismodegib—Dermatitis—Imiquimod—skin cancer	0.000105	0.00472	CcSEcCtD
Vismodegib—SHH—Signaling Pathways—RHOU—skin cancer	0.000104	0.00196	CbGpPWpGaD
Vismodegib—Myalgia—Temozolomide—skin cancer	0.000104	0.00468	CcSEcCtD
Vismodegib—Arthralgia—Temozolomide—skin cancer	0.000104	0.00468	CcSEcCtD
Vismodegib—Unspecified disorder of skin and subcutaneous tissue—Temozolomide—skin cancer	0.000103	0.00465	CcSEcCtD
Vismodegib—Decreased appetite—Bleomycin—skin cancer	0.000103	0.00463	CcSEcCtD
Vismodegib—Pain—Bleomycin—skin cancer	0.000101	0.00455	CcSEcCtD
Vismodegib—Musculoskeletal discomfort—Dactinomycin—skin cancer	0.0001	0.00452	CcSEcCtD
Vismodegib—SMO—Signaling Pathways—RHOU—skin cancer	9.89e-05	0.00186	CbGpPWpGaD
Vismodegib—Nausea—Imiquimod—skin cancer	9.89e-05	0.00445	CcSEcCtD
Vismodegib—Nervous system disorder—Temozolomide—skin cancer	9.78e-05	0.0044	CcSEcCtD
Vismodegib—Skin disorder—Temozolomide—skin cancer	9.69e-05	0.00436	CcSEcCtD
Vismodegib—SHH—Differentiation Pathway—IL6—skin cancer	9.66e-05	0.00182	CbGpPWpGaD
Vismodegib—Myalgia—Fluorouracil—skin cancer	9.59e-05	0.00432	CcSEcCtD
Vismodegib—Decreased appetite—Dactinomycin—skin cancer	9.59e-05	0.00432	CcSEcCtD
Vismodegib—Fatigue—Dactinomycin—skin cancer	9.51e-05	0.00428	CcSEcCtD
Vismodegib—ABCG2—Fluoropyrimidine Activity—ERCC2—skin cancer	9.5e-05	0.00179	CbGpPWpGaD
Vismodegib—Pain—Dactinomycin—skin cancer	9.43e-05	0.00425	CcSEcCtD
Vismodegib—CYP3A4—female reproductive system—skin cancer	9.32e-05	0.00394	CbGeAlD
Vismodegib—ABCB1—HIF-1-alpha transcription factor network—PLIN2—skin cancer	9.27e-05	0.00175	CbGpPWpGaD
Vismodegib—Connective tissue disorder—Docetaxel—skin cancer	9.17e-05	0.00413	CcSEcCtD
Vismodegib—Musculoskeletal discomfort—Temozolomide—skin cancer	9.09e-05	0.00409	CcSEcCtD
Vismodegib—Gastrointestinal pain—Dactinomycin—skin cancer	9.02e-05	0.00406	CcSEcCtD
Vismodegib—Nervous system disorder—Fluorouracil—skin cancer	9.01e-05	0.00406	CcSEcCtD
Vismodegib—ABCB1—epithelium—skin cancer	8.88e-05	0.00375	CbGeAlD
Vismodegib—Dyspepsia—Temozolomide—skin cancer	8.78e-05	0.00395	CcSEcCtD
Vismodegib—Abdominal pain—Dactinomycin—skin cancer	8.72e-05	0.00392	CcSEcCtD
Vismodegib—Decreased appetite—Temozolomide—skin cancer	8.67e-05	0.0039	CcSEcCtD
Vismodegib—SHH—Signaling by GPCR—PTCH2—skin cancer	8.62e-05	0.00162	CbGpPWpGaD
Vismodegib—Gastrointestinal disorder—Temozolomide—skin cancer	8.61e-05	0.00388	CcSEcCtD
Vismodegib—Fatigue—Temozolomide—skin cancer	8.6e-05	0.00387	CcSEcCtD
Vismodegib—Pain—Temozolomide—skin cancer	8.53e-05	0.00384	CcSEcCtD
Vismodegib—Constipation—Temozolomide—skin cancer	8.53e-05	0.00384	CcSEcCtD
Vismodegib—Asthenia—Bleomycin—skin cancer	8.48e-05	0.00382	CcSEcCtD
Vismodegib—Musculoskeletal discomfort—Fluorouracil—skin cancer	8.37e-05	0.00377	CcSEcCtD
Vismodegib—Pruritus—Bleomycin—skin cancer	8.36e-05	0.00377	CcSEcCtD
Vismodegib—Alopecia—Docetaxel—skin cancer	8.25e-05	0.00371	CcSEcCtD
Vismodegib—SHH—Integrated Pancreatic Cancer Pathway—CDK4—skin cancer	8.22e-05	0.00155	CbGpPWpGaD
Vismodegib—SMO—GPCR ligand binding—SHH—skin cancer	8.2e-05	0.00155	CbGpPWpGaD
Vismodegib—SHH—GPCR ligand binding—SMO—skin cancer	8.2e-05	0.00155	CbGpPWpGaD
Vismodegib—SHH—GPCR ligand binding—PTCH1—skin cancer	8.2e-05	0.00155	CbGpPWpGaD
Vismodegib—SMO—Signaling by GPCR—PTCH2—skin cancer	8.17e-05	0.00154	CbGpPWpGaD
Vismodegib—Gastrointestinal pain—Temozolomide—skin cancer	8.16e-05	0.00367	CcSEcCtD
Vismodegib—Malnutrition—Docetaxel—skin cancer	8.13e-05	0.00366	CcSEcCtD
Vismodegib—Dyspepsia—Fluorouracil—skin cancer	8.09e-05	0.00364	CcSEcCtD
Vismodegib—Decreased appetite—Fluorouracil—skin cancer	7.99e-05	0.0036	CcSEcCtD
Vismodegib—SHH—GPCR ligand binding—PTGER4—skin cancer	7.99e-05	0.0015	CbGpPWpGaD
Vismodegib—Dysgeusia—Docetaxel—skin cancer	7.96e-05	0.00358	CcSEcCtD
Vismodegib—Gastrointestinal disorder—Fluorouracil—skin cancer	7.93e-05	0.00357	CcSEcCtD
Vismodegib—Asthenia—Dactinomycin—skin cancer	7.91e-05	0.00356	CcSEcCtD
Vismodegib—Abdominal pain—Temozolomide—skin cancer	7.88e-05	0.00355	CcSEcCtD
Vismodegib—Back pain—Docetaxel—skin cancer	7.86e-05	0.00354	CcSEcCtD
Vismodegib—Pain—Fluorouracil—skin cancer	7.86e-05	0.00354	CcSEcCtD
Vismodegib—ABCG2—lymph node—skin cancer	7.83e-05	0.00331	CbGeAlD
Vismodegib—Muscle spasms—Docetaxel—skin cancer	7.81e-05	0.00352	CcSEcCtD
Vismodegib—SMO—Integrated Pancreatic Cancer Pathway—CDK4—skin cancer	7.79e-05	0.00147	CbGpPWpGaD
Vismodegib—SMO—GPCR ligand binding—PTCH1—skin cancer	7.78e-05	0.00146	CbGpPWpGaD
Vismodegib—ABCB1—mammalian vulva—skin cancer	7.7e-05	0.00326	CbGeAlD
Vismodegib—SMO—GPCR ligand binding—PTGER4—skin cancer	7.57e-05	0.00143	CbGpPWpGaD
Vismodegib—Diarrhoea—Dactinomycin—skin cancer	7.54e-05	0.0034	CcSEcCtD
Vismodegib—Vomiting—Bleomycin—skin cancer	7.52e-05	0.00338	CcSEcCtD
Vismodegib—Rash—Bleomycin—skin cancer	7.45e-05	0.00336	CcSEcCtD
Vismodegib—Dermatitis—Bleomycin—skin cancer	7.45e-05	0.00335	CcSEcCtD
Vismodegib—Asthenia—Temozolomide—skin cancer	7.16e-05	0.00322	CcSEcCtD
Vismodegib—Pruritus—Temozolomide—skin cancer	7.06e-05	0.00318	CcSEcCtD
Vismodegib—Nausea—Bleomycin—skin cancer	7.02e-05	0.00316	CcSEcCtD
Vismodegib—Vomiting—Dactinomycin—skin cancer	7.01e-05	0.00316	CcSEcCtD
Vismodegib—Rash—Dactinomycin—skin cancer	6.95e-05	0.00313	CcSEcCtD
Vismodegib—Myalgia—Docetaxel—skin cancer	6.92e-05	0.00311	CcSEcCtD
Vismodegib—Arthralgia—Docetaxel—skin cancer	6.92e-05	0.00311	CcSEcCtD
Vismodegib—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—skin cancer	6.87e-05	0.00309	CcSEcCtD
Vismodegib—ABCB1—lymphoid tissue—skin cancer	6.84e-05	0.00289	CbGeAlD
Vismodegib—Diarrhoea—Temozolomide—skin cancer	6.82e-05	0.00307	CcSEcCtD
Vismodegib—ABCB1—female reproductive system—skin cancer	6.6e-05	0.00279	CbGeAlD
Vismodegib—Nausea—Dactinomycin—skin cancer	6.55e-05	0.00295	CcSEcCtD
Vismodegib—Nervous system disorder—Docetaxel—skin cancer	6.5e-05	0.00293	CcSEcCtD
Vismodegib—Pruritus—Fluorouracil—skin cancer	6.5e-05	0.00293	CcSEcCtD
Vismodegib—Skin disorder—Docetaxel—skin cancer	6.44e-05	0.0029	CcSEcCtD
Vismodegib—Vomiting—Temozolomide—skin cancer	6.34e-05	0.00285	CcSEcCtD
Vismodegib—Rash—Temozolomide—skin cancer	6.29e-05	0.00283	CcSEcCtD
Vismodegib—Diarrhoea—Fluorouracil—skin cancer	6.29e-05	0.00283	CcSEcCtD
Vismodegib—Dermatitis—Temozolomide—skin cancer	6.28e-05	0.00283	CcSEcCtD
Vismodegib—SHH—Signaling by GPCR—MC1R—skin cancer	6.23e-05	0.00117	CbGpPWpGaD
Vismodegib—Musculoskeletal discomfort—Docetaxel—skin cancer	6.04e-05	0.00272	CcSEcCtD
Vismodegib—Nausea—Temozolomide—skin cancer	5.92e-05	0.00267	CcSEcCtD
Vismodegib—SMO—Signaling by GPCR—MC1R—skin cancer	5.91e-05	0.00111	CbGpPWpGaD
Vismodegib—SHH—Integrated Pancreatic Cancer Pathway—PTGS2—skin cancer	5.88e-05	0.00111	CbGpPWpGaD
Vismodegib—Vomiting—Fluorouracil—skin cancer	5.84e-05	0.00263	CcSEcCtD
Vismodegib—Dyspepsia—Docetaxel—skin cancer	5.84e-05	0.00263	CcSEcCtD
Vismodegib—Rash—Fluorouracil—skin cancer	5.79e-05	0.00261	CcSEcCtD
Vismodegib—Dermatitis—Fluorouracil—skin cancer	5.79e-05	0.00261	CcSEcCtD
Vismodegib—Decreased appetite—Docetaxel—skin cancer	5.77e-05	0.0026	CcSEcCtD
Vismodegib—Gastrointestinal disorder—Docetaxel—skin cancer	5.73e-05	0.00258	CcSEcCtD
Vismodegib—Fatigue—Docetaxel—skin cancer	5.72e-05	0.00257	CcSEcCtD
Vismodegib—Constipation—Docetaxel—skin cancer	5.67e-05	0.00255	CcSEcCtD
Vismodegib—Pain—Docetaxel—skin cancer	5.67e-05	0.00255	CcSEcCtD
Vismodegib—SMO—Integrated Pancreatic Cancer Pathway—PTGS2—skin cancer	5.57e-05	0.00105	CbGpPWpGaD
Vismodegib—SHH—Disease—CSPG4—skin cancer	5.51e-05	0.00104	CbGpPWpGaD
Vismodegib—ABCB1—head—skin cancer	5.51e-05	0.00233	CbGeAlD
Vismodegib—Nausea—Fluorouracil—skin cancer	5.46e-05	0.00246	CcSEcCtD
Vismodegib—Gastrointestinal pain—Docetaxel—skin cancer	5.42e-05	0.00244	CcSEcCtD
Vismodegib—Abdominal pain—Docetaxel—skin cancer	5.24e-05	0.00236	CcSEcCtD
Vismodegib—ABCG2—HIF-1-alpha transcription factor network—TERT—skin cancer	5.12e-05	0.000963	CbGpPWpGaD
Vismodegib—SHH—Signaling Pathways—PTCH2—skin cancer	5.09e-05	0.000959	CbGpPWpGaD
Vismodegib—SMO—Signaling Pathways—PTCH2—skin cancer	4.83e-05	0.000909	CbGpPWpGaD
Vismodegib—Asthenia—Docetaxel—skin cancer	4.76e-05	0.00214	CcSEcCtD
Vismodegib—Pruritus—Docetaxel—skin cancer	4.69e-05	0.00211	CcSEcCtD
Vismodegib—Diarrhoea—Docetaxel—skin cancer	4.54e-05	0.00204	CcSEcCtD
Vismodegib—Vomiting—Docetaxel—skin cancer	4.22e-05	0.0019	CcSEcCtD
Vismodegib—SHH—Signaling by GPCR—PTCH1—skin cancer	4.21e-05	0.000793	CbGpPWpGaD
Vismodegib—SHH—Signaling by GPCR—SMO—skin cancer	4.21e-05	0.000793	CbGpPWpGaD
Vismodegib—SMO—Signaling by GPCR—SHH—skin cancer	4.21e-05	0.000793	CbGpPWpGaD
Vismodegib—Rash—Docetaxel—skin cancer	4.18e-05	0.00188	CcSEcCtD
Vismodegib—Dermatitis—Docetaxel—skin cancer	4.18e-05	0.00188	CcSEcCtD
Vismodegib—SHH—Signaling by GPCR—PTGER4—skin cancer	4.1e-05	0.000772	CbGpPWpGaD
Vismodegib—SMO—Signaling by GPCR—PTCH1—skin cancer	3.99e-05	0.000752	CbGpPWpGaD
Vismodegib—Nausea—Docetaxel—skin cancer	3.94e-05	0.00177	CcSEcCtD
Vismodegib—SHH—Integrated Pancreatic Cancer Pathway—KRAS—skin cancer	3.94e-05	0.000741	CbGpPWpGaD
Vismodegib—SMO—Signaling by GPCR—PTGER4—skin cancer	3.89e-05	0.000732	CbGpPWpGaD
Vismodegib—SHH—Signaling Pathways—GLI2—skin cancer	3.86e-05	0.000727	CbGpPWpGaD
Vismodegib—ABCB1—lymph node—skin cancer	3.86e-05	0.00163	CbGeAlD
Vismodegib—SHH—Disease—ENO2—skin cancer	3.75e-05	0.000706	CbGpPWpGaD
Vismodegib—SMO—Integrated Pancreatic Cancer Pathway—KRAS—skin cancer	3.73e-05	0.000703	CbGpPWpGaD
Vismodegib—SHH—Signaling Pathways—MC1R—skin cancer	3.68e-05	0.000693	CbGpPWpGaD
Vismodegib—SMO—Signaling Pathways—GLI2—skin cancer	3.66e-05	0.000689	CbGpPWpGaD
Vismodegib—SHH—Signaling Pathways—GLI1—skin cancer	3.63e-05	0.000683	CbGpPWpGaD
Vismodegib—SHH—Integrated Pancreatic Cancer Pathway—TP53—skin cancer	3.5e-05	0.000659	CbGpPWpGaD
Vismodegib—SMO—Signaling Pathways—MC1R—skin cancer	3.49e-05	0.000657	CbGpPWpGaD
Vismodegib—SMO—Signaling Pathways—GLI1—skin cancer	3.44e-05	0.000648	CbGpPWpGaD
Vismodegib—SHH—Signaling Pathways—SUFU—skin cancer	3.44e-05	0.000648	CbGpPWpGaD
Vismodegib—ABCG2—Fluoropyrimidine Activity—TP53—skin cancer	3.39e-05	0.000639	CbGpPWpGaD
Vismodegib—ALB—SLC-mediated transmembrane transport—SLC12A2—skin cancer	3.35e-05	0.000631	CbGpPWpGaD
Vismodegib—SMO—Integrated Pancreatic Cancer Pathway—TP53—skin cancer	3.32e-05	0.000624	CbGpPWpGaD
Vismodegib—SMO—Signaling Pathways—SUFU—skin cancer	3.26e-05	0.000614	CbGpPWpGaD
Vismodegib—SHH—Disease—FOXO4—skin cancer	3.05e-05	0.000575	CbGpPWpGaD
Vismodegib—ABCB1—HIF-1-alpha transcription factor network—TERT—skin cancer	2.77e-05	0.000521	CbGpPWpGaD
Vismodegib—ABCG2—Transmembrane transport of small molecules—SLC12A2—skin cancer	2.76e-05	0.00052	CbGpPWpGaD
Vismodegib—SHH—Signaling Pathways—RASA1—skin cancer	2.61e-05	0.000491	CbGpPWpGaD
Vismodegib—CYP2C8—Arachidonic acid metabolism—PTGS2—skin cancer	2.54e-05	0.000478	CbGpPWpGaD
Vismodegib—SMO—Signaling Pathways—SHH—skin cancer	2.49e-05	0.000468	CbGpPWpGaD
Vismodegib—SHH—Signaling Pathways—PTCH1—skin cancer	2.49e-05	0.000468	CbGpPWpGaD
Vismodegib—SHH—Signaling Pathways—SMO—skin cancer	2.49e-05	0.000468	CbGpPWpGaD
Vismodegib—SMO—Signaling Pathways—RASA1—skin cancer	2.47e-05	0.000465	CbGpPWpGaD
Vismodegib—SHH—Signaling Pathways—PTGER4—skin cancer	2.42e-05	0.000456	CbGpPWpGaD
Vismodegib—SMO—Signaling Pathways—PTCH1—skin cancer	2.36e-05	0.000444	CbGpPWpGaD
Vismodegib—SMO—Signaling Pathways—PTGER4—skin cancer	2.3e-05	0.000432	CbGpPWpGaD
Vismodegib—CYP2C19—Arachidonic acid metabolism—PTGS2—skin cancer	2.26e-05	0.000426	CbGpPWpGaD
Vismodegib—SHH—Disease—ERCC2—skin cancer	2.18e-05	0.00041	CbGpPWpGaD
Vismodegib—ABCB1—Integrated Pancreatic Cancer Pathway—SHH—skin cancer	2.17e-05	0.000409	CbGpPWpGaD
Vismodegib—SHH—Signaling Pathways—FOXO4—skin cancer	2.14e-05	0.000403	CbGpPWpGaD
Vismodegib—CYP2C9—Arachidonic acid metabolism—PTGS2—skin cancer	2.06e-05	0.000389	CbGpPWpGaD
Vismodegib—ABCB1—Integrated Pancreatic Cancer Pathway—SMO—skin cancer	2.06e-05	0.000388	CbGpPWpGaD
Vismodegib—SHH—Disease—TERT—skin cancer	2.04e-05	0.000384	CbGpPWpGaD
Vismodegib—SMO—Signaling Pathways—FOXO4—skin cancer	2.03e-05	0.000382	CbGpPWpGaD
Vismodegib—CYP2C8—Metabolism of lipids and lipoproteins—PLIN2—skin cancer	1.9e-05	0.000358	CbGpPWpGaD
Vismodegib—ALB—Metabolism of lipids and lipoproteins—PLIN2—skin cancer	1.89e-05	0.000356	CbGpPWpGaD
Vismodegib—ALB—Transmembrane transport of small molecules—SLC12A2—skin cancer	1.7e-05	0.000321	CbGpPWpGaD
Vismodegib—CYP2C19—Metabolism of lipids and lipoproteins—PLIN2—skin cancer	1.7e-05	0.000319	CbGpPWpGaD
Vismodegib—SHH—Disease—BRAF—skin cancer	1.62e-05	0.000304	CbGpPWpGaD
Vismodegib—ALB—Selenium Micronutrient Network—PTGS2—skin cancer	1.6e-05	0.000302	CbGpPWpGaD
Vismodegib—CYP2C9—Metabolism of lipids and lipoproteins—PLIN2—skin cancer	1.55e-05	0.000291	CbGpPWpGaD
Vismodegib—ABCB1—Transmembrane transport of small molecules—SLC12A2—skin cancer	1.49e-05	0.000281	CbGpPWpGaD
Vismodegib—SHH—Signaling Pathways—TERT—skin cancer	1.43e-05	0.000269	CbGpPWpGaD
Vismodegib—ABCG2—Metabolism—PLIN2—skin cancer	1.36e-05	0.000257	CbGpPWpGaD
Vismodegib—SMO—Signaling Pathways—TERT—skin cancer	1.35e-05	0.000255	CbGpPWpGaD
Vismodegib—ALB—Vitamin B12 Metabolism—IL6—skin cancer	1.35e-05	0.000255	CbGpPWpGaD
Vismodegib—SHH—Disease—PTGS2—skin cancer	1.3e-05	0.000246	CbGpPWpGaD
Vismodegib—SHH—Signaling by GPCR—NRAS—skin cancer	1.2e-05	0.000227	CbGpPWpGaD
Vismodegib—ALB—Folate Metabolism—TP53—skin cancer	1.2e-05	0.000226	CbGpPWpGaD
Vismodegib—SMO—Signaling by GPCR—NRAS—skin cancer	1.14e-05	0.000215	CbGpPWpGaD
Vismodegib—SHH—Signaling Pathways—BRAF—skin cancer	1.13e-05	0.000213	CbGpPWpGaD
Vismodegib—ALB—Folate Metabolism—IL6—skin cancer	1.1e-05	0.000207	CbGpPWpGaD
Vismodegib—ABCG2—Metabolism—CSPG4—skin cancer	1.1e-05	0.000207	CbGpPWpGaD
Vismodegib—SMO—Signaling Pathways—BRAF—skin cancer	1.07e-05	0.000202	CbGpPWpGaD
Vismodegib—ABCB1—Integrated Pancreatic Cancer Pathway—CDK4—skin cancer	1.06e-05	0.000199	CbGpPWpGaD
Vismodegib—SHH—Signaling by GPCR—KRAS—skin cancer	1.04e-05	0.000195	CbGpPWpGaD
Vismodegib—SHH—Disease—NRAS—skin cancer	1.02e-05	0.000191	CbGpPWpGaD
Vismodegib—SMO—Signaling by GPCR—KRAS—skin cancer	9.82e-06	0.000185	CbGpPWpGaD
Vismodegib—SHH—Signaling by GPCR—HRAS—skin cancer	8.81e-06	0.000166	CbGpPWpGaD
Vismodegib—ALB—Selenium Micronutrient Network—IL6—skin cancer	8.74e-06	0.000165	CbGpPWpGaD
Vismodegib—SHH—Disease—KRAS—skin cancer	8.74e-06	0.000165	CbGpPWpGaD
Vismodegib—CYP2C8—Metabolism—PLIN2—skin cancer	8.46e-06	0.000159	CbGpPWpGaD
Vismodegib—SHH—Signaling by GPCR—IL6—skin cancer	8.43e-06	0.000159	CbGpPWpGaD
Vismodegib—ALB—Metabolism—PLIN2—skin cancer	8.41e-06	0.000158	CbGpPWpGaD
Vismodegib—SMO—Signaling by GPCR—HRAS—skin cancer	8.35e-06	0.000157	CbGpPWpGaD
Vismodegib—SMO—Signaling by GPCR—IL6—skin cancer	7.99e-06	0.00015	CbGpPWpGaD
Vismodegib—ABCB1—Integrated Pancreatic Cancer Pathway—PTGS2—skin cancer	7.56e-06	0.000142	CbGpPWpGaD
Vismodegib—CYP2C19—Metabolism—PLIN2—skin cancer	7.55e-06	0.000142	CbGpPWpGaD
Vismodegib—ABCG2—Metabolism—ENO2—skin cancer	7.47e-06	0.000141	CbGpPWpGaD
Vismodegib—SHH—Disease—HRAS—skin cancer	7.43e-06	0.00014	CbGpPWpGaD
Vismodegib—ABCB1—Metabolism—PLIN2—skin cancer	7.37e-06	0.000139	CbGpPWpGaD
Vismodegib—SHH—Signaling Pathways—NRAS—skin cancer	7.11e-06	0.000134	CbGpPWpGaD
Vismodegib—SHH—Disease—IL6—skin cancer	7.11e-06	0.000134	CbGpPWpGaD
Vismodegib—CYP2C9—Metabolism—PLIN2—skin cancer	6.88e-06	0.00013	CbGpPWpGaD
Vismodegib—CYP2C8—Metabolism—CSPG4—skin cancer	6.82e-06	0.000128	CbGpPWpGaD
Vismodegib—ALB—Metabolism—CSPG4—skin cancer	6.78e-06	0.000128	CbGpPWpGaD
Vismodegib—SMO—Signaling Pathways—NRAS—skin cancer	6.74e-06	0.000127	CbGpPWpGaD
Vismodegib—SHH—Signaling Pathways—KRAS—skin cancer	6.12e-06	0.000115	CbGpPWpGaD
Vismodegib—CYP2C19—Metabolism—CSPG4—skin cancer	6.09e-06	0.000115	CbGpPWpGaD
Vismodegib—ABCB1—Metabolism—CSPG4—skin cancer	5.94e-06	0.000112	CbGpPWpGaD
Vismodegib—SMO—Signaling Pathways—KRAS—skin cancer	5.8e-06	0.000109	CbGpPWpGaD
Vismodegib—CYP2C9—Metabolism—CSPG4—skin cancer	5.55e-06	0.000104	CbGpPWpGaD
Vismodegib—SHH—Signaling Pathways—TP53—skin cancer	5.44e-06	0.000102	CbGpPWpGaD
Vismodegib—SHH—Signaling Pathways—HRAS—skin cancer	5.2e-06	9.8e-05	CbGpPWpGaD
Vismodegib—SMO—Signaling Pathways—TP53—skin cancer	5.16e-06	9.71e-05	CbGpPWpGaD
Vismodegib—ABCB1—Integrated Pancreatic Cancer Pathway—KRAS—skin cancer	5.06e-06	9.54e-05	CbGpPWpGaD
Vismodegib—SHH—Signaling Pathways—IL6—skin cancer	4.98e-06	9.38e-05	CbGpPWpGaD
Vismodegib—SMO—Signaling Pathways—HRAS—skin cancer	4.93e-06	9.29e-05	CbGpPWpGaD
Vismodegib—SMO—Signaling Pathways—IL6—skin cancer	4.72e-06	8.89e-05	CbGpPWpGaD
Vismodegib—CYP2C8—Metabolism—ENO2—skin cancer	4.63e-06	8.73e-05	CbGpPWpGaD
Vismodegib—ALB—Metabolism—ENO2—skin cancer	4.61e-06	8.68e-05	CbGpPWpGaD
Vismodegib—CYP3A4—Metabolism—PLIN2—skin cancer	4.54e-06	8.55e-05	CbGpPWpGaD
Vismodegib—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—skin cancer	4.5e-06	8.48e-05	CbGpPWpGaD
Vismodegib—ABCG2—Metabolism—ERCC2—skin cancer	4.34e-06	8.17e-05	CbGpPWpGaD
Vismodegib—CYP2C19—Metabolism—ENO2—skin cancer	4.14e-06	7.79e-05	CbGpPWpGaD
Vismodegib—ABCB1—Metabolism—ENO2—skin cancer	4.04e-06	7.6e-05	CbGpPWpGaD
Vismodegib—CYP2C9—Metabolism—ENO2—skin cancer	3.77e-06	7.1e-05	CbGpPWpGaD
Vismodegib—CYP3A4—Metabolism—CSPG4—skin cancer	3.66e-06	6.89e-05	CbGpPWpGaD
Vismodegib—CYP2C8—Metabolism of lipids and lipoproteins—PTGS2—skin cancer	3.62e-06	6.83e-05	CbGpPWpGaD
Vismodegib—ALB—Metabolism of lipids and lipoproteins—PTGS2—skin cancer	3.6e-06	6.79e-05	CbGpPWpGaD
Vismodegib—CYP2C19—Metabolism of lipids and lipoproteins—PTGS2—skin cancer	3.23e-06	6.09e-05	CbGpPWpGaD
Vismodegib—ALB—Hemostasis—NRAS—skin cancer	3.08e-06	5.8e-05	CbGpPWpGaD
Vismodegib—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—skin cancer	2.95e-06	5.56e-05	CbGpPWpGaD
Vismodegib—CYP2C8—Metabolism—ERCC2—skin cancer	2.69e-06	5.07e-05	CbGpPWpGaD
Vismodegib—ALB—Metabolism—ERCC2—skin cancer	2.68e-06	5.04e-05	CbGpPWpGaD
Vismodegib—ALB—Hemostasis—KRAS—skin cancer	2.65e-06	4.99e-05	CbGpPWpGaD
Vismodegib—ABCG2—Metabolism—PTGS2—skin cancer	2.6e-06	4.9e-05	CbGpPWpGaD
Vismodegib—CYP3A4—Metabolism—ENO2—skin cancer	2.49e-06	4.68e-05	CbGpPWpGaD
Vismodegib—CYP2C19—Metabolism—ERCC2—skin cancer	2.4e-06	4.52e-05	CbGpPWpGaD
Vismodegib—ALB—Hemostasis—TP53—skin cancer	2.36e-06	4.44e-05	CbGpPWpGaD
Vismodegib—ABCB1—Metabolism—ERCC2—skin cancer	2.35e-06	4.42e-05	CbGpPWpGaD
Vismodegib—ALB—Hemostasis—HRAS—skin cancer	2.25e-06	4.24e-05	CbGpPWpGaD
Vismodegib—CYP2C9—Metabolism—ERCC2—skin cancer	2.19e-06	4.13e-05	CbGpPWpGaD
Vismodegib—CYP2C8—Metabolism—PTGS2—skin cancer	1.61e-06	3.04e-05	CbGpPWpGaD
Vismodegib—ALB—Metabolism—PTGS2—skin cancer	1.6e-06	3.02e-05	CbGpPWpGaD
Vismodegib—CYP3A4—Metabolism—ERCC2—skin cancer	1.44e-06	2.72e-05	CbGpPWpGaD
Vismodegib—CYP2C19—Metabolism—PTGS2—skin cancer	1.44e-06	2.71e-05	CbGpPWpGaD
Vismodegib—ABCB1—Metabolism—PTGS2—skin cancer	1.41e-06	2.65e-05	CbGpPWpGaD
Vismodegib—CYP2C9—Metabolism—PTGS2—skin cancer	1.31e-06	2.47e-05	CbGpPWpGaD
Vismodegib—CYP3A4—Metabolism—PTGS2—skin cancer	8.66e-07	1.63e-05	CbGpPWpGaD
